ONO-7913 Phase I Study (ONO-7913)

Ono Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Solid Tumor

Treatments: Biological: ONO-7913

Study type: Interventional

Funder types: Industry

Identifiers

NCT04403308

ONO-7913-01

Details and patient eligibility

About

To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.

Enrollment: 7 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with histologically or cytologically confirmed advanced or metastatic solid tumors
2. ECOG Performance Status of 0-1
3. Patients with life expectancy of at least 3 months

Exclusion criteria

1. Patients with multiple cancers
2. Patients with history of serious allergy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

ONO-7913 as a Single Agent

Experimental group

Treatment:

Biological: ONO-7913